Radiation has been a mainstay cancer therapy for almost 100 years. But its potent cell-killing power, so effective against tumors, is a double-edged sword when healthy tissue gets in the way.

Cancer Biology PhD student Travis Fischer has been selected for the University of Iowa's 2025 Dare to Discover campaign for his work in immunotherapies.

With support from a Holden Comprehensive Cancer Center pilot grant, a research team aims to improve the patient experience of the diagnostic period.

Four early-career scientists have each been awarded a one-year, $40,000 American Cancer Society Institutional Research Grant through University of Iowa Holden Comprehensive Cancer Center.

Trial will test whether a personalized mRNA vaccine combined with an immunotherapy prevents melanoma from recurring

Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment? That was the intriguing question that led University of Iowa researchers and their colleagues to develop a drinkable, carbon monoxide-infused foam that boosted the effectiveness of the therapy, known as autophagy inhibition, in mice and human cells. The findings were recently published in the journal Advanced Science.

With the conventional first-line drug for early-stage bladder cancer in severe shortage, new therapies developed at Iowa are poised to lead a new wave of care.

The treatment uses 3D technology to precisely map tumor removal and develop prosthetics that are unique to each patient’s anatomy. It’s helping patients get back to their active lifestyles sooner.

University of Iowa Holden Comprehensive Cancer Center has received its fourth renewal as a comprehensive cancer center from the National Cancer Institute (NCI), part of the National Institutes of Health.